Exelixis
EXEL
#1617
Rank
C$14.85 B
Marketcap
$53.07
Share price
-1.08%
Change (1 day)
70.83%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : C$1.01 Billion

According to Exelixis's latest financial reports the company's total liabilities are C$1.01 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31C$1.00 B12.18%
2023-12-31C$0.89 B13.74%
2022-12-31C$0.79 B53.05%
2021-12-31C$0.51 B57.01%
2020-12-31C$0.32 B26.24%
2019-12-31C$0.26 B42.01%
2018-12-31C$0.18 B-60.55%
2017-12-31C$0.46 B-31.58%
2016-12-31C$0.68 B3.69%
2015-12-31C$0.65 B29.1%
2014-12-31C$0.50 B9.28%
2013-12-31C$0.46 B10.17%
2012-12-31C$0.42 B37.18%
2011-12-31C$0.30 B-47.73%
2010-12-31C$0.58 B10.36%
2009-12-31C$0.53 B-4.15%
2008-12-31C$0.55 B70.87%
2007-12-31C$0.32 B-8.19%
2006-12-31C$0.35 B10.68%
2005-12-31C$0.32 B10.93%
2004-12-31C$0.28 B13.51%
2003-12-31C$0.25 B-1.2%
2002-12-31C$0.25 B47.9%
2001-12-31C$0.17 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$83.93 B 8,172.93%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$82.45 B 8,027.00%๐Ÿ‡ซ๐Ÿ‡ท France
C$102.00 B 9,954.77%๐Ÿ‡บ๐Ÿ‡ธ USA
C$109.91 B 10,733.89%๐Ÿ‡บ๐Ÿ‡ธ USA
C$123.96 B 12,119.42%๐Ÿ‡บ๐Ÿ‡ธ USA
C$156.63 B 15,339.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$180.12 B 17,654.27%๐Ÿ‡บ๐Ÿ‡ธ USA
C$73.84 M-92.72%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.10 B-89.71%๐Ÿ‡บ๐Ÿ‡ธ USA